Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours
esmo - Findings from the PYNNACLE study
AI Summary: Clinical results from the PYNNACLE program demonstrate that rezatapopt, an oral small‑molecule p53 reactivator, produces antitumor activity in cancers driven by the TP53 Y220C mutation. Early data validate targeting a previously “undruggable” p53 variant, offering a concrete therapeutic strategy and sparking excitement — and a few warranted caveats — about broader applicability.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Belzutifan combinations highlighted at ASCO GU improve RCC outcomes / 2 months
Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in MIBC / 3 months
TTLC 2026 highlights advanced NSCLC symposia and emerging data / 3 months
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 2 months
HORMAD1 emerges as a potential target in triple‑negative breast cancer / 2 months
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 2 months
Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Government Policy, Eli Lilly, Hospital Operations, Genetics and look for the RSS link.
StackHealth Time Machine